Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gigacloud Technology Inc (GCT) vs Pfizer Inc (PFE) Price & Performance

Gigacloud Technology IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs Pfizer Inc — how do they compare? Gigacloud Technology Inc trades at $37.83 (market cap $1.40B), while Pfizer Inc trades at $25.26 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 101× Gigacloud Technology Inc's market cap, and Pfizer Inc pays a 6.93% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.

GCTPFE
Market Cap
$1.40B$141.46B
Sector
TechnologyHealth
52-Week High
$51.80$28.56
52-Week Low
$20.97$23.29
Enterprise Value
$1.51B$192.12B
Volume
29,869,932
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.

GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE